A special opportunity for lovers of mass spectrometry proteomics to join a like-minded team at PTI. Join a collaborative initiative to enable direct protein analysis at unprecedented scale, in partnership with leading instrument developers, academics, and industry leaders. 1/2

So you sequenced a billion+ bases. That don’t impress me much. JERBOA is a toolkit to figure out what genes do at scale. We've used it to unlock 43 non-model microbes across 12 different phyla.

We’re testing conceptual hypotheses, dissecting disease progression, proteostasis, protein degradation, PTMs, and aggregation, all with focus on creative, rigorous data interpretation. If you want to do science that changes how we think, this is it. 👇 jobs.lever.co/convergentre...

🔥 We’re hiring! A rare opportunity to rethink neurodegeneration: 🟦 Develop creative, rigorous approaches to data interpretation toward mechanistic insights. Join our team at PTI to study neurodegenerative disease using direct protein analysis at single-cell resolution. 1/2

Light-microscopy brain mapping was picked as one of 7 technologies to watch in 2026 by Nature! Hear from E11's CEO @andrewcpayne.bsky.social: www.nature.com/articles/d41...

Today, Merge Labs announced its launch as a new research lab pursuing long-horizon R&D in ultrasound-based neural technology, with $252 million in funding from OpenAI, Bain Capital, Gabe Newell, and others. www.essentialtechnology.blog/p/announcing...

The focussed research organizations enabled by @convergentresearch.bsky.social are driving forward an ambitious agenda ! youtu.be/L5W-lV1K_xQ?...

As metascience advances, we could see unprecedented collaboration between disciplines, accelerating innovation. Imagine a world where scientific breakthroughs happen at lightning speed! #futurism

It's been an incredibly exciting year in metascience at large, and for us at Convergent. Last week, the NSF announced their Tech Labs Initiative. www.essentialtechnology.blog/p/the-future...

A mission control for frontier technology An ambitious perspective on technological innovation and scaling by @convergentresearch.bsky.social youtu.be/L5W-lV1K_xQ?...

NSF said it will select around three topic areas “in which the U.S. must retain or regain technical dominance,” possibly including quantum technology, AI, critical materials, semiconductor manufacturing, and biotechnology. www.aip.org/fyi/nsf-to-i...

happy wednesday from new orleans! here's some @convergentresearch.bsky.social Essential Technology art that doesn't hit the feed (only the frontispiece gets shared here) - first from our most recent piece on the @NSF's new Tech Labs Initiative www.essentialtechnology.blog/p/the-future...

2025 was a turning point for mCDR. Across OAE and DOC, the field moved from promise to proof: pilots advanced, first verified credits were delivered, and new standards, permits, and infrastructure took shape. We recap some of the year’s key industry milestones here: www.cworthy.org/blog/year-in...

This article is from people who have thought about FROs for years and have experience with what works and what doesn't. I have always appreciated the restraint in defining the niche of FROs in the broader ecosystem; it comes out clearly in this piece. www.essentialtechnology.blog/p/the-future...

Last Friday, the @NSF released an RFI for a new Tech Labs Initiative, to "build and scale next-gen independent research organizations to advance science."

To mark the occasion, FAS CEO Daniel Correa spoke with @sgrodriques.bsky.social and @adammarblestone.bsky.social about how best to run a Tech Lab/FRO-style org, what they've learned, and the role federal funding can play: fas.org/publication/...

If you've been interested in FROs, you'll want to see this from NSF: sam.gov/opp/7332ade9... "sustained... support to... independent organizational structures operating outside of existing academic, start-up, and industry constraints... a dedicated, full-time team... operational independence..."

New data is live!! With 25 new kinases, we have a total of 420,497 drug-target interaction results! There are multiple ways to access the dataset 🧵

To be sure you know about each new data release, subscribe to our "latest news" email list at 🔗 data.evebio.org

The 25 new kinases added tomorrow will bring EvE's dataset to 67 total kinases, in addition to 85 7-transmembrane receptors and 32 nuclear receptors. All of these have activity measurements (or confirmed inactivity) for our 1,400 compound small molecule drug library.

It's the final day of our data release preview -- data will be posted tomorrow! The last five new targets to preview are metabolic and regulatory kinases: YES, FER, FES, PASK1, and CCK2

These less-characterized kinases represent the expanding frontier of cancer target space. Meanwhile, our previous release already includes well-established oncology targets like EGFR, BTK, and Aurora kinases -- along with EGFR and BTK mutants. Explore those results: 🔗 data.evebio.org

Day 5 of our kinase preview for our imminent data release: Emerging Oncology Targets We're adding four kinases gaining traction in cancer drug discovery: PVK2, SVK, TBK1, and CGK2.

Among all proteome changes in Alzheimer’s disease (AD), 20S proteasomes stand out. ⬛️ Their abundance strongly declines in AD patients. => This decline parallels a reduction in 20S substrate proteins and leads to abnormal protein accumulation in AD. biorxiv.org/content/10.1...

For the day 3 preview of EvE's kinase data release, the theme is calcium. We're adding three "calcium decoders" to our dataset: CaMK2a, CaMKK2, and MLK1.

If you'd like to explore our released data, in addition to downloads and programmatic access, we have an interactive data exploration app. Follow the Explore Data link here: 🔗 data.evebio.org

Day 2 preview of EvE's kinase data release: The RSK Family We're adding 5 ribosomal S6 kinases to our dataset: RSK1, RSK2, RSK3, RSK4, and p70S6K. These kinases are key effectors of the MAPK signaling pathway, and are important targets in cancer research.

Congrats to Arlo Sheridan and Will Patton for releasing Volara, our first open-source library for scalable image processing, and also for a great technical writeup!

Wonderful to collaborate with, and to support as an advisor, E11 Bio - and to announce PRISM, a technology for mapping brains in a self-correcting way, by barcoding neurons followed by expansion microscopy! Thread below by E11 Bio CEO Andrew Payne, with preprint at, www.biorxiv.org/content/10.1...

Thanks to AWS for hosting our data sets as described in their blog post: aws.amazon.com/blogs/public...

You can also access our data on Hugging Face 🔗 huggingface.co/datasets/eve...

Stay tuned for Day 2! In the meantime, explore our existing dataset: 159 targets × 1,397 small molecule drugs. 🔗 data.evebio.org

We're starting with some classics: PKCα, PKCγ, PKCθ, and PKN1 - protein kinase C isoforms that have been cancer drug targets for decades.

At EvE, we release data regularly, and our next release is coming up next week! We're adding 25 more kinases to our public drug-target interaction dataset. Over the next 6 days, we'll preview what's coming. Day 1: The PKC Family

Thanksgiving reminds me how fortunate I am to collaborate with research teams (@parallelsq.bsky.social, @slavovlab.bsky.social) who combine rigor, imagination, and openness. I’m grateful for the blue-sky thinking that fuels discovery, and for the spirit of sharing that makes progress possible.

Increased exon-10 inclusion elevates tau with 4 microtubule-binding repeats (4R) and contributes to neuronal degeneration. In addition to 4R, many other tau proteoforms are associated with Alzheimer’s and other neurodegenerative disorders. 𝐏𝐫𝐨𝐭𝐞𝐨𝐟𝐨𝐫𝐦 𝐝𝐲𝐬𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐭𝐨 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲.

Congratulations to @cworthy.org on their announcement today! Learn more about this wonderful FRO here: www.youtube.com/watch?v=DA-e...

[C]Worthy has secured multi-year support from ORCA and the Patrick J. McGovern Foundation to scale open, trusted science tools for ocean-based carbon removal. We can’t scale what we can’t measure—this funding accelerates our MRV models + datasets. Full announcement: www.cworthy.org/media/cworth...

One experiment to highlight is with Cupriavidus necator. We used a bayesian optimizer in optuna to select electroporation conditions, a robot to run the experiments, and then the optimizer selected the next cycle of experiments. Landed on a protocol a bit better than the literature best in 3 cycles!

Have a look if you are interested in how the team at @cultivarium.bsky.social is finding electroporation protocols for new microbes: both screening lots of conditions on a custom built electroporator concurrently, and cyclical iteration using bayesian optimization www.biorxiv.org/content/10.1...

As we continue EvE's mission, we're excited to see our work impact the drug development, ML, and AI communities. More to come!

👥 Leadership news: @ehouskee.bsky.social steps into the CEO role, leading us into our next phase, while founding CEO William Busa continues as EvE's Chief Scientific Officer.

🤖 @futurehousesf.bsky.social used our data in the development of the ether0 chemistry reasoning model, showing the value of experimental group truth data for scientific AI models.

💻 Our pharmome mapping data is now accessible to ML developers on @hf.co, making our purpose-built drug-target interaction data easily accessible for model development. huggingface.co/blog/hugging...

🤝 We're partnering with DrugBank to integrate our drug-target interaction data into their drug intelligence platform, bringing it directly to the drug development community with rich context and annotation. go.drugbank.com/evebio

We're excited to share several new developments. Our pharmome mapping dataset is now more accessible and integrated than ever, and the use cases we imagined are coming to life! 🧪 evebio.org/pharmome-dat... Here's what's new: 🧵

Announced today: @evebio.bsky.social's pharmome-mapping dataset - the largest public map of how compounds do or don’t touch druggable targets - is now live on DrugBank's knowledgebase and available programmatically + interactively on Hugging Face, @hf.co. Learn more: evebio.org/pharmome-dat...